Lanean...
Rituximab Exhibits Altered Pharmacokinetics in Patients with Membranous Nephropathy
BACKGROUND: Rituximab (RTX) is a chimeric monoclonal anti-CD20 antibody used off-label in the treatment of membranous nephropathy (MN). Unfortunately, limited information is available on the pharmacokinetics of therapeutic proteins such as RTX in patients with glomerular kidney diseases. OBJECTIVE:...
Gorde:
| Argitaratua izan da: | Ann Pharmacother |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6629258/ https://ncbi.nlm.nih.gov/pubmed/30293439 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1060028018803587 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|